Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.
You may also be interested in...
Alzheon Revives Failed Alzheimer's Drug With Genetic Subtype Approach
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago